PRNewsWire
25 Jul 2026, 02:00 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
ADMA Biologics is facing a securities class action lawsuit alleging the use of 'channel stuffing' to artificially inflate revenue. — Allegations of revenue manipulation through channel stuffing are severe and typically lead to significant stock price devaluation and loss of investor trust.
-0.80The lawsuit alleges that ADMA Biologics engaged in undisclosed related party transactions and lacked adequate internal controls. — Failures in internal controls and hidden related-party deals suggest systemic corporate governance risks and potential accounting irregularities.
-0.60Investors who acquired ADMA securities between August 9, 2024, and March 25, 2026, have until August 10, 2026, to file lead plaintiff applications. — While procedural, the deadline for lead plaintiff applications confirms the legal process is advancing, maintaining downward pressure on the stock.
-0.20Which stocks this story touches
Continue reading
6 related stories
Search tags
The company is mentioned as being subject to a securities class action lawsuit.
The company is facing a securities class action lawsuit alleging channel stuffing and failure to disclose material information.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
3h ago
